• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

韩国分化型甲状腺癌肺转移的长期预后及其预后因素。

Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors.

机构信息

1 Department of Internal Medicine, Seoul National University , Seoul, Korea.

出版信息

Thyroid. 2014 Feb;24(2):277-86. doi: 10.1089/thy.2012.0654. Epub 2013 Sep 11.

DOI:10.1089/thy.2012.0654
PMID:23758653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3926138/
Abstract

BACKGROUND

Distant metastasis, generally to lung and bone, is rare in differentiated thyroid carcinoma (DTC) and the prognosis is still elusive. We investigated long-term outcomes of lung metastasis in DTC patients and its prognostic factors.

METHODS

A retrospective review was performed of 4572 patients who underwent surgery for DTC from 1962 to 2009 at Seoul National University Hospital. Among them, 164 patients were identified with lung metastasis and 152 patients were enrolled in the final analysis. Poor prognosis was defined as progressive disease or death.

RESULTS

Of these 152 patients, 10- and 20-year survival rates were 85.0% and 71.0%, respectively. No evidence of disease, stable disease, progressive disease, and death was identified in 22.4%, 28.3%, 35.5%, and 13.8%, respectively, after 11 years of median follow-up (range 2-41 years). Older age at diagnosis (≥45 years), primary tumor size ≥2 cm, follicular thyroid cancer, metastasis diagnosed after initial evaluation or (131)I remnant ablation (late metastasis), multiple metastases other than lung, (131)I nonavidity, and the presence of macronodules (≥1 cm) were more frequent in poor prognoses. Cox proportional hazard ratio for progression-free survival showed that (131)I nonavidity was the only independent predictive factor for poor prognosis.

CONCLUSIONS

The prognosis of lung metastasis from DTC in Korea within this study was favorable. (131)I nonavidity, observed more frequently in late metastasis, was the only independent factor predicting poor prognosis.

摘要

背景

远处转移,通常转移至肺部和骨骼,在分化型甲状腺癌(DTC)中较为罕见,且预后仍难以捉摸。我们研究了 DTC 患者肺部转移的长期结果及其预后因素。

方法

对 1962 年至 2009 年在首尔国立大学医院接受 DTC 手术的 4572 例患者进行了回顾性分析。其中,有 164 例患者被诊断为肺部转移,152 例患者被纳入最终分析。预后不良定义为疾病进展或死亡。

结果

在这 152 例患者中,10 年和 20 年的生存率分别为 85.0%和 71.0%。在中位数为 11 年的随访时间(范围 2-41 年)后,分别有 22.4%、28.3%、35.5%和 13.8%的患者无疾病证据、稳定疾病、疾病进展和死亡。诊断时年龄较大(≥45 岁)、原发肿瘤大小≥2cm、滤泡性甲状腺癌、初始评估后或(131)I 残余消融(晚期转移)时诊断转移、除肺部以外的多处转移、(131)I 非摄取和存在大结节(≥1cm)的患者预后较差。无进展生存的 Cox 比例风险比显示,(131)I 非摄取是不良预后的唯一独立预测因素。

结论

本研究中韩国 DTC 肺部转移的预后良好。(131)I 非摄取在晚期转移中更为常见,是唯一预测不良预后的独立因素。

相似文献

1
Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors.韩国分化型甲状腺癌肺转移的长期预后及其预后因素。
Thyroid. 2014 Feb;24(2):277-86. doi: 10.1089/thy.2012.0654. Epub 2013 Sep 11.
2
RISK FACTORS FOR NONREMISSION AND PROGRESSION-FREE SURVIVAL AFTER I-131 THERAPY IN PATIENTS WITH LUNG METASTASIS FROM DIFFERENTIATED THYROID CANCER: A SINGLE-INSTITUTE, RETROSPECTIVE ANALYSIS IN SOUTHERN CHINA.分化型甲状腺癌肺转移碘-131 治疗后未缓解及无进展生存的危险因素:中国南方单中心回顾性分析。
Endocr Pract. 2016 Sep;22(9):1048-56. doi: 10.4158/EP151139.OR. Epub 2016 Apr 28.
3
Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up.分化型甲状腺癌肺转移患者长期随访结局的预后指标。
Clin Endocrinol (Oxf). 2018 Feb;88(2):318-326. doi: 10.1111/cen.13489. Epub 2017 Oct 27.
4
Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up.分化型甲状腺癌远处转移老年患者(≥65 岁)接受碘 131 治疗及随访后的长期结局和预后。
Front Endocrinol (Lausanne). 2021 Feb 25;11:588024. doi: 10.3389/fendo.2020.588024. eCollection 2020.
5
Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.评估伴有远处转移的分化型甲状腺癌患者与癌症特异性生存相关的预后因素。
Ann Surg Oncol. 2013 Apr;20(4):1329-35. doi: 10.1245/s10434-012-2711-x. Epub 2012 Oct 28.
6
Evaluation of Prognostic Factors Associated With Differentiated Thyroid Carcinoma With Pulmonary Metastasis.评估与分化型甲状腺癌肺转移相关的预后因素。
Clin Nucl Med. 2016 Dec;41(12):917-921. doi: 10.1097/RLU.0000000000001426.
7
Efficacy of radioiodine therapy for treating 20 patients with pulmonary metastases from differentiated thyroid cancer and a meta-analysis of the current literature.放射性碘治疗对 20 例分化型甲状腺癌肺转移患者的疗效及当前文献的荟萃分析。
Clin Transl Oncol. 2018 Jul;20(7):928-935. doi: 10.1007/s12094-017-1792-1. Epub 2017 Nov 8.
8
Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.青少年与成年患者远处转移性分化型甲状腺癌(DTC)的放射性碘(RAI)治疗
Endocr J. 2015;62(12):1067-75. doi: 10.1507/endocrj.EJ15-0451. Epub 2015 Oct 1.
9
Oncologic outcomes in patients with 1-cm to 4-cm differentiated thyroid carcinoma according to extent of thyroidectomy.根据甲状腺切除术的范围,1 至 4 厘米分化型甲状腺癌患者的肿瘤学结果。
Head Neck. 2019 Jan;41(1):56-63. doi: 10.1002/hed.25356. Epub 2018 Dec 10.
10
Initial Size of Metastatic Lesions Is Best Prognostic Factor in Patients with Metastatic Differentiated Thyroid Carcinoma Confined to the Lung.对于局限于肺部的转移性分化型甲状腺癌患者,转移灶的初始大小是最佳预后因素。
Thyroid. 2017 Jan;27(1):49-58. doi: 10.1089/thy.2016.0347. Epub 2016 Nov 15.

引用本文的文献

1
Clinical outcome and influencing factors of differentiated thyroid cancer patients with radioiodine-refractory lung metastasis.分化型甲状腺癌碘难治性肺转移患者的临床结局及影响因素
Front Endocrinol (Lausanne). 2025 Aug 4;16:1622539. doi: 10.3389/fendo.2025.1622539. eCollection 2025.
2
Which factors affect treatment success/prognosis in thyroid cancers with pulmonary metastases and what is/how should be the effective cumulative cure/dose as a current approach; a retrospective study.哪些因素影响甲状腺癌肺转移的治疗成功率/预后,以及作为当前方法的有效累积治愈剂量是多少/应该是多少;一项回顾性研究。
Ann Nucl Med. 2025 May 19. doi: 10.1007/s12149-025-02060-5.
3
Tumor-to-tumor metastases: systematic review and meta-analysis of 685 reported cases.肿瘤间转移:对685例报告病例的系统评价和荟萃分析
Clin Exp Metastasis. 2025 Jan 31;42(2):14. doi: 10.1007/s10585-025-10332-7.
4
Survival trends and conditional survival in patients with pulmonary metastases from differentiated thyroid carcinoma.分化型甲状腺癌肺转移患者的生存趋势及条件生存情况
Endocrine. 2025 Mar;87(3):1120-1130. doi: 10.1007/s12020-024-04109-3. Epub 2024 Nov 26.
5
Comparative Uptake Patterns of Radioactive Iodine and [18F]-Fluorodeoxyglucose (FDG) in Metastatic Differentiated Thyroid Cancers.放射性碘与[18F]-氟脱氧葡萄糖(FDG)在转移性分化型甲状腺癌中的摄取模式比较
J Clin Med. 2024 Jul 6;13(13):3963. doi: 10.3390/jcm13133963.
6
Automatic prediction of non-iodine-avid status in lung metastases for radioactive I treatment in differentiated thyroid cancer patients.自动预测分化型甲状腺癌患者放射性碘治疗中肺转移灶的非碘摄取状态。
Front Endocrinol (Lausanne). 2024 Jun 11;15:1429115. doi: 10.3389/fendo.2024.1429115. eCollection 2024.
7
Development and validation of a lung metastases-predicting nomogram for intermediate- to high-risk differentiated thyroid carcinoma patients.中高危分化型甲状腺癌患者肺转移预测列线图的开发与验证
Future Oncol. 2024;20(22):1575-1586. doi: 10.1080/14796694.2024.2354161. Epub 2024 Jun 13.
8
Papillary Thyroid Cancer Trends in the Wake of the COVID-19 Pandemic: Is There a Shift toward a More Aggressive Entity?COVID-19大流行后甲状腺乳头状癌的趋势:是否正转向更具侵袭性的类型?
Diseases. 2024 Mar 20;12(3):62. doi: 10.3390/diseases12030062.
9
Cytosolic Cadherin 4 promotes angiogenesis and metastasis in papillary thyroid cancer by suppressing the ubiquitination/degradation of β-catenin.细胞质钙黏蛋白 4 通过抑制β-连环蛋白的泛素化/降解促进甲状腺乳头状癌的血管生成和转移。
J Transl Med. 2024 Feb 24;22(1):201. doi: 10.1186/s12967-024-05012-1.
10
The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib.索拉非尼治疗放射性碘难治性甲状腺癌患者的疗效和安全性。
Front Endocrinol (Lausanne). 2023 Jul 18;14:1200932. doi: 10.3389/fendo.2023.1200932. eCollection 2023.

本文引用的文献

1
Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades.韩国过去四十年甲状腺癌临床病理特征和结局的变化。
Thyroid. 2013 Jul;23(7):797-804. doi: 10.1089/thy.2012.0329. Epub 2013 Jun 21.
2
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.索拉非尼增强晚期甲状腺癌的放射性碘摄取。
N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288.
3
Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.评估伴有远处转移的分化型甲状腺癌患者与癌症特异性生存相关的预后因素。
Ann Surg Oncol. 2013 Apr;20(4):1329-35. doi: 10.1245/s10434-012-2711-x. Epub 2012 Oct 28.
4
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009.韩国癌症统计数据:2009 年的发病率、死亡率、生存率和患病率。
Cancer Res Treat. 2012 Mar;44(1):11-24. doi: 10.4143/crt.2012.44.1.11. Epub 2012 Mar 31.
5
The long-term outcomes of the second generation of familial nonmedullary thyroid carcinoma are more aggressive than sporadic cases.第二代家族性非髓样甲状腺癌的长期预后比散发性病例更具侵袭性。
Thyroid. 2012 Apr;22(4):356-62. doi: 10.1089/thy.2011.0163. Epub 2012 Jan 26.
6
Long-term outcomes of distant metastasis from differentiated thyroid carcinoma.分化型甲状腺癌远处转移的长期预后。
Clin Endocrinol (Oxf). 2012 Mar;76(3):439-47. doi: 10.1111/j.1365-2265.2011.04231.x.
7
The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.BRAF(V600E) 突变与甲状腺乳头癌预后因素及不良临床结局的相关性:一项荟萃分析。
Cancer. 2012 Apr 1;118(7):1764-73. doi: 10.1002/cncr.26500. Epub 2011 Aug 31.
8
Mutational and clinico-pathological analysis of papillary thyroid carcinoma in Serbia.塞尔维亚甲状腺乳头癌的突变与临床病理分析。
Endocr J. 2011;58(5):381-93. doi: 10.1507/endocrj.k11e-054. Epub 2011 Apr 15.
9
Radiation exposure does not significantly contribute to the risk of recurrence of Chernobyl thyroid cancer.辐射暴露对切尔诺贝利甲状腺癌复发的风险没有显著影响。
J Clin Endocrinol Metab. 2011 Feb;96(2):385-93. doi: 10.1210/jc.2010-1634. Epub 2010 Nov 17.
10
Increasing incidence of differentiated thyroid cancer in South East England: 1987-2006.东南英格兰分化型甲状腺癌发病率的上升:1987-2006 年。
Eur Arch Otorhinolaryngol. 2011 Jun;268(6):899-906. doi: 10.1007/s00405-010-1416-7. Epub 2010 Nov 12.